{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:21:30Z","timestamp":1783088490288,"version":"3.54.6"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["TY2025001"],"award-info":[{"award-number":["TY2025001"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["BMU2025PYJH033"],"award-info":[{"award-number":["BMU2025PYJH033"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","award":["2024-2-4075"],"award-info":[{"award-number":["2024-2-4075"]}],"id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L232126"],"award-info":[{"award-number":["L232126"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","phiro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physics and Imaging in Radiation Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.phro.2026.100980","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:13:27Z","timestamp":1777130007000},"page":"100980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["External beam focal boost radiotherapy to intraprostatic lesions in prostate cancer: a scoping review"],"prefix":"10.1016","volume":"39","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangbin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianshu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phro.2026.100980_b0005","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.phro.2026.100980_b0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.phro.2026.100980_b0015","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.phro.2026.100980_b0020","unstructured":"National Comprehensive Cancer Network. Prostate Cancer, Version 2. 2026. NCCN Clinical Practice Guidelines in Oncology https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.phro.2026.100980_b0025","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.juro.2015.06.100","article-title":"Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer","volume":"194","author":"Zumsteg","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.phro.2026.100980_b0030","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0040","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.eururo.2011.08.029","article-title":"Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes","volume":"60","author":"Zelefsky","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.phro.2026.100980_b0045","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","article-title":"Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials","volume":"74","author":"Viani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.radonc.2015.01.021","article-title":"Gross tumor volume and clinical target volume in prostate cancer: how do satellites relate to the index lesion","volume":"115","author":"Hollmann","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0055","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.eururo.2022.01.029","article-title":"Simultaneous integrated micro-boost: reigniting the FLAME for dose escalation in prostate cancer?","volume":"82","author":"Zumsteg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.phro.2026.100980_b0060","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0360-3016(02)02795-5","article-title":"Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning","volume":"53","author":"Cellini","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijrobp.2007.03.065","article-title":"Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence","volume":"69","author":"Pucar","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0070","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","article-title":"Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study","volume":"82","author":"Arrayeh","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0075","doi-asserted-by":"crossref","unstructured":"Zhao Y, Haworth A, Rowshanfarzad P, Ebert MA. Focal boost in prostate cancer radiotherapy: a review of planning studies and clinical trials. Cancers (Basel) 2023;15. https:\/\/doi.org\/10.3390\/cancers15194888.","DOI":"10.3390\/cancers15194888"},{"key":"10.1016\/j.phro.2026.100980_b0080","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.euo.2022.10.001","article-title":"Magnetic resonance imaging-guided focal boost to intraprostatic lesions using external beam radiotherapy for localized prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Poon","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0085","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00345-023-04745-w","article-title":"Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review","volume":"42","author":"Dornisch","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.phro.2026.100980_b0090","doi-asserted-by":"crossref","DOI":"10.1002\/pros.24888","article-title":"Propensity score matched analysis of external beam radiotherapy with or without focal boost to intraprostatic lesions in prostate cancer","author":"Onal","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.phro.2026.100980_b0095","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/pros.24558","article-title":"Treatment outcomes of simultaneous integrated boost to intraprostatic lesions with external beam radiotherapy in localized prostate cancer patients","volume":"83","author":"Onal","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.phro.2026.100980_b0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/0284186X.2021.1998613","article-title":"Long-term outcome of biologically guided dose-escalated radiotherapy of localized prostate cancer","volume":"61","author":"Kuisma","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.921465","article-title":"Long-term outcomes of prostate intensity-modulated radiation therapy incorporating a simultaneous intra-prostatic MRI-directed boost","volume":"12","author":"Laughlin","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0110","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210683","article-title":"MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial","volume":"95","author":"Zapatero","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.phro.2026.100980_b0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","article-title":"Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer","volume":"82","author":"Groen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.phro.2026.100980_b0120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0125","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2020.01.052","article-title":"Phase I trial of MRI-guided prostate cancer lattice extreme ablative dose (LEAD) boost radiation therapy","volume":"107","author":"Pollack","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0130","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.21873\/anticanres.14672","article-title":"Simultaneous integrated radiotherapy boost to the dominant intraprostatic lesion: final results of a phase I\/II trial","volume":"40","author":"Buwenge","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.phro.2026.100980_b0135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2017.12.022","article-title":"Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial","volume":"127","author":"Monninkhof","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0140","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00066-018-1282-6","article-title":"Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET\/CT : clinical results and quality of life","volume":"194","author":"Schlenter","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.phro.2026.100980_b0145","first-page":"252","article-title":"Effect of modern, high-quality prostate intensity-modulated radiation therapy on outcome: evidence from a community radiation oncology program","volume":"7","author":"Kao","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0150","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ijrobp.2017.01.219","article-title":"A prospective trial of intensity modulated radiation therapy (IMRT) incorporating a simultaneous integrated boost for prostate cancer: long-term outcomes compared with standard image guided IMRT","volume":"97","author":"Schild","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0155","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clon.2015.09.006","article-title":"Prostate dose-painting radiotherapy and radiobiological guided optimisation enhances the therapeutic ratio","volume":"28","author":"Uzan","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.phro.2026.100980_b0160","first-page":"16","article-title":"Clinical and technical feasibility of ultra-boost irradiation in dominant intraprostatic lesion by tomotherapy: preliminary experience and revision of literature","volume":"58","author":"Garibaldi","year":"2016","journal-title":"Panminerva Med"},{"key":"10.1016\/j.phro.2026.100980_b0165","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.radonc.2016.04.031","article-title":"Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: analysis of genito-urinary and rectal toxicity","volume":"119","author":"Sundahl","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0170","article-title":"Early outcome of prostate intensity modulated radiation therapy (IMRT) incorporating a simultaneous intra-prostatic MRI directed boost. OMICS","volume":"3","author":"Schild","year":"2014","journal-title":"J Radiol"},{"key":"10.1016\/j.phro.2026.100980_b0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1748-717X-7-14","article-title":"Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost","volume":"7","author":"Pinkawa","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0180","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/COC.0b013e318209cd8f","article-title":"Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity","volume":"35","author":"Ippolito","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0185","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/j.ijrobp.2011.01.048","article-title":"Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging","volume":"81","author":"Wong","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0190","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2008.01.040","article-title":"Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion","volume":"72","author":"Fonteyne","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0195","doi-asserted-by":"crossref","DOI":"10.1111\/cas.16429","article-title":"Highly hypofractionated biaxially rotational dynamic radiation therapy (BROAD-RT) for high-risk prostate cancer","author":"Aizawa","year":"2025","journal-title":"Cancer Sci"},{"key":"10.1016\/j.phro.2026.100980_b0200","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/j.clon.2024.08.011","article-title":"Long-term results of hypofractionated radiotherapy with intra-prostatic boosts in men with intermediate- and high-risk prostate cancer: a phase II trial","volume":"36","author":"Chatterjee","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.phro.2026.100980_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110089","article-title":"Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial","volume":"193","author":"Fonteyne","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0210","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0215","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0220","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5603\/RPOR.a2022.0041","article-title":"Feasibility and safety of definite volumetric modulated arc therapy with simultaneous integrated boost to the dominant intraprostatic lesion in patients with unfavorable intermediate to high-risk prostate cancer","volume":"27","author":"Dankulchai","year":"2022","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.phro.2026.100980_b0225","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200571","article-title":"Multiparametric prostate MRI-based intensity-modulated radiation therapy guided by prostatic calcifications","volume":"93","author":"Kao","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.phro.2026.100980_b0230","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ijrobp.2019.11.402","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: efficacy and toxicity in the DELINEATE trial","volume":"106","author":"Murray","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0235","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ijrobp.2017.12.016","article-title":"4 weeks versus 5weeks of hypofractionated high-dose radiation therapy as primary therapy for prostate cancer: interim safety analysis of a randomized phase 3 trial","volume":"100","author":"Fonteyne","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0240","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.clon.2016.09.009","article-title":"Twenty fraction prostate radiotherapy with intra-prostatic boost: results of a pilot study","volume":"29","author":"Onjukka","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.phro.2026.100980_b0245","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.radonc.2013.08.006","article-title":"Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome","volume":"109","author":"Fonteyne","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0250","article-title":"PSMA-PET guided intra-prostatic boost in prostate SBRT (PROBE): a phase II trial","author":"Singh","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0255","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2024.03.009","article-title":"Simultaneous focal boost with stereotactic radiation therapy for localized intermediate- to high-risk prostate cancer: primary outcomes of the SPARC phase 2 trial","volume":"120","author":"Yasar","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0260","doi-asserted-by":"crossref","unstructured":"Draulans C, Haustermans K, Pos FJ, van der Heide UA, De Cock L, van der Voort van Zyp J, et al. Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial. Radiother Oncol 2024;201:110568. https:\/\/doi.org\/10.1016\/j.radonc.2024.110568.","DOI":"10.1016\/j.radonc.2024.110568"},{"key":"10.1016\/j.phro.2026.100980_b0265","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16112097","article-title":"Spatial distribution of recurrence and long-term toxicity following dose escalation to the dominant intra-prostatic nodule for intermediate-high-risk prostate cancer: insights from a phase I\/II study","volume":"16","author":"Clo\u00eetre","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phro.2026.100980_b0270","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00345-024-04876-8","article-title":"Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial \u201cGIVE ME FIVE\u201d","volume":"42","author":"Marvaso","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.phro.2026.100980_b0275","article-title":"Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer \u2013 acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial","volume":"46","author":"Fink","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0280","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ijrobp.2024.06.038","article-title":"Acute toxicity and early prostate specific antigen response after two-fraction stereotactic radiation therapy for localized prostate cancer using peri-rectal spacing-initial report of the SABR-dual trial","volume":"120","author":"Fredman","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0285","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2023.09.032","article-title":"Interim toxicity analysis from the randomized HERMES trial of 2- and 5-fraction magnetic resonance imaging-guided adaptive prostate radiation therapy","volume":"118","author":"Westley","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0290","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00066-023-02189-0","article-title":"Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: adose-escalation trial (DESTROY-4)","volume":"200","author":"Deodato","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.phro.2026.100980_b0295","article-title":"Toxicity profile and clinical outcomes of stereotactic body radiotherapy with afocal boost without fiducials or perirectal hydrogel spacer for localized prostate cancer","author":"Tsurugai","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.phro.2026.100980_b0300","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.prro.2023.05.004","article-title":"Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: 5-year toxicity and biochemical recurrence results from a prospective trial","volume":"13","author":"Maas","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0305","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijrobp.2023.05.004","article-title":"Toxicity and patient-reported quality-of-life outcomes after prostate stereotactic body radiation therapy with focal boost to magnetic resonance imaging-identified prostate cancer lesions: results of a phase 2 trial","volume":"117","author":"Morris","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109503","article-title":"Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - results from the 2SMART phase 2 trial","volume":"181","author":"Ong","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0315","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijrobp.2023.02.054","article-title":"A randomized feasibility trial of stereotactic prostate radiation therapy with or without elective nodal irradiation in high-risk localized prostate cancer (SPORT trial)","volume":"117","author":"Houlihan","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109441","article-title":"SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: an analysis of the dosimetric impact of intra-fractional organ changes","volume":"179","author":"Brennan","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109713","article-title":"From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial","volume":"185","author":"De Cock","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0330","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220803","article-title":"Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I\/II study","volume":"96","author":"Cloitre","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1016\/j.phro.2026.100980_b0335","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijrobp.2021.10.137","article-title":"SABR for high-risk prostate cancer: a prospective multilevel MRI-based dose escalation trial","volume":"113","author":"Hannan","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0340","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijrobp.2019.12.044","article-title":"Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate SABR: a toxicity and quality-of-life comparison of two prospective trials","volume":"107","author":"Alayed","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0345","first-page":"88","article-title":"Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: initial results of the SPARC trial","volume":"25","author":"Nicholls","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0350","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12032-020-01397-3","article-title":"Phase II prospective trial \u201cgive me five\u201d short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218)","volume":"37","author":"Marvaso","year":"2020","journal-title":"Med Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0355","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijrobp.2018.09.023","article-title":"50-Gy stereotactic body radiation therapy to the dominant intraprostatic nodule: results from a phase 1a\/b trial","volume":"103","author":"Herrera","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0360","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.adro.2018.09.007","article-title":"Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: acute toxicity and dosimetry results from a prospective trial","volume":"4","author":"McDonald","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0365","article-title":"Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of phase II trial AIRC-IG-13218","volume":"91","author":"Timon","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.phro.2026.100980_b0370","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1748-717X-8-84","article-title":"Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results","volume":"8","author":"Aluwini","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0375","doi-asserted-by":"crossref","unstructured":"Draulans C, van der Heide UA, Haustermans K, Pos FJ, van der Voort van Zyp J, De Boer H, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol 2020;147:92-98. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.015.","DOI":"10.1016\/j.radonc.2020.03.015"},{"key":"10.1016\/j.phro.2026.100980_b0380","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/02841860410002824","article-title":"The radiobiology of prostate cancer including new aspects of fractionated radiotherapy","volume":"44","author":"Fowler","year":"2005","journal-title":"Acta Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0385","doi-asserted-by":"crossref","DOI":"10.1007\/s00066-025-02376-1","article-title":"Optimizing treatment for Gleason10 prostate cancer: radiation dose escalation and (68)Ga-PSMA-PET\/CT staging","author":"Onal","year":"2025","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.phro.2026.100980_b0390","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijrobp.2023.07.044","article-title":"Risk modeling for individualization of the FLAME focal boost approach in external beam radiation therapy for patients with localized prostate cancer","volume":"118","author":"Menne Guricov\u00e1","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0395","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.phro.2026.100980_b0400","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.clgc.2023.01.007","article-title":"Early safety and efficacy profile of homogeneously dosed salvage stereotactic body radiotherapy (SBRT) for intraprostatic recurrences after low dose rate (LDR) brachytherapy","volume":"21","author":"Nikitas","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.phro.2026.100980_b0405","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2967\/jnumed.118.212563","article-title":"Outcome after PSMA PET\/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis","volume":"60","author":"Schmidt-Hegemann","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.phro.2026.100980_b0410","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.ijrobp.2024.02.014","article-title":"A phase 1 trial of salvage stereotactic body radiation therapy for radiorecurrent prostate cancer after brachytherapy","volume":"119","author":"Patel","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0415","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.prro.2024.09.017","article-title":"F(18)-DCFPyL PSMA-PET\/CT versus MRI: identifying the prostate cancer region most at risk of radiation therapy recurrence for tumor dose escalation","volume":"15","author":"Belliveau","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0420","doi-asserted-by":"crossref","DOI":"10.1148\/rg.230112","article-title":"MRI and PSMA PET\/CT of biochemical recurrence of prostate cancer","volume":"43","author":"Awiwi","year":"2023","journal-title":"Radiographics"},{"key":"10.1016\/j.phro.2026.100980_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110070","article-title":"Using multiparametric magnetic resonance imaging and prostate specific membrane antigen positron emission tomography to detect and delineate the gross tumour volume of intraprostatic lesions - a systematic review and meta-analysis","volume":"192","author":"Dhar","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0430","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic (68)Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.phro.2026.100980_b0435","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ijrobp.2015.02.004","article-title":"Comparison of [(11)C]choline positron emission tomography with T2- and diffusion-weighted magnetic resonance imaging for delineating malignant intraprostatic lesions","volume":"92","author":"Chang","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0440","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.radonc.2020.08.008","article-title":"Histologic validation of auto-contoured dominant intraprostatic lesions on [(18)F] DCFPyL PSMA-PET imaging","volume":"152","author":"Alfano","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0445","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1148\/radiol.2019190687","article-title":"Diagnostic accuracy of multiparametric MRI versus (68)Ga-PSMA-11 PET\/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer","volume":"293","author":"Muehlematter","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.phro.2026.100980_b0450","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2023.07.004","volume":"117","author":"Lui","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0455","article-title":"Enhancing prostate-cancer-specific MRI by genetic amplified nanoparticle tumor homing","volume":"31","author":"Zhao","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.phro.2026.100980_b0460","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.radonc.2019.07.030","article-title":"Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT)","volume":"141","author":"Alexander","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0465","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/j.ijrobp.2017.06.311","article-title":"Longer-term androgen deprivation therapy improves cancer-specific survival in patients with gleason score 9-10 prostate adenocarcinoma: an individual patient-level meta-analysis of RTOG 8531, 8610, and 9202","volume":"99","author":"Kishan","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100980_b0470","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.radonc.2011.12.007","article-title":"The effect of hormonal treatment on conspicuity of prostate cancer: implications for focal boosting radiotherapy","volume":"103","author":"Groenendaal","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0475","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160818","article-title":"Effect of androgen deprivation therapy on intraprostatic tumour volume identified on (18)F choline PET\/CT for prostate dose painting radiotherapy","volume":"90","author":"Chan","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.phro.2026.100980_b0480","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.22.00970","article-title":"Sequencing of androgen-deprivation therapy of short duration with radiotherapy for nonmetastatic prostate cancer (SANDSTORM): a pooled analysis of 12 randomized trials","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0485","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00066-018-1402-3","article-title":"Impact of androgen deprivation therapy on apparent diffusion coefficient and T2w MRI for histogram and texture analysis with respect to focal radiotherapy of prostate cancer","volume":"195","author":"Daniel","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.phro.2026.100980_b0490","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00259-022-06047-6","volume":"50","author":"Ke","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.phro.2026.100980_b0495","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(05)01737-7","article-title":"Theragnostic imaging for radiation oncology: dose-painting by numbers","volume":"6","author":"Bentzen","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0500","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.zemedi.2016.02.002","article-title":"Personalized precision radiotherapy by integration of multi-parametric functional and biological imaging in prostate cancer: a feasibility study","volume":"27","author":"Thorwarth","year":"2017","journal-title":"Z Med Phys"},{"key":"10.1016\/j.phro.2026.100980_b0505","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/mp.16264","article-title":"Patient-specific voxel-level dose prescription for prostate cancer radiotherapy considering tumor cell density and grade distribution","volume":"50","author":"Zhao","year":"2023","journal-title":"Med Phys"},{"key":"10.1016\/j.phro.2026.100980_b0510","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1002\/mp.16936","article-title":"Towards optimal heterogeneous prostate radiotherapy dose prescriptions based on patient-specific or population-based biological features","volume":"51","author":"Zhao","year":"2024","journal-title":"Med Phys"},{"key":"10.1016\/j.phro.2026.100980_b0515","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13014-019-1209-0","article-title":"Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO)","volume":"14","author":"Carl","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0520","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/pros.24693","article-title":"The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer","volume":"84","author":"Onal","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.phro.2026.100980_b0525","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/curroncol31020072","article-title":"Electromagnetic transmitter-based prostate gating for dose-escalated linac-based stereotactic body radiation therapy: an evaluation of intrafraction motion","volume":"31","author":"De Bari","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0530","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.883725","article-title":"Intrafraction prostate motion management during dose-escalated linac-based stereotactic body radiation therapy","volume":"12","author":"Panizza","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0535","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1002\/mp.15660","article-title":"Experimental investigation of dynamic real-time rotation-including dose reconstruction during prostate tracking radiotherapy","volume":"49","author":"Muurholm","year":"2022","journal-title":"Med Phys"},{"key":"10.1016\/j.phro.2026.100980_b0540","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2009.03.013","article-title":"Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer","volume":"92","author":"Fonteyne","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0545","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"167","author":"Groen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109864","article-title":"Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer","volume":"188","author":"Ong","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0555","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11604-020-01023-2","article-title":"Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-\/very high-risk prostate cancer: a dosimetric analysis of toxicity","volume":"38","author":"Sakurai","year":"2020","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.phro.2026.100980_b0560","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/COC.0b013e3182546821","article-title":"Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review","volume":"37","author":"Ishiyama","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0565","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2011.09.027","article-title":"Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature","volume":"61","author":"Bud\u00e4us","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.phro.2026.100980_b0570","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.06.011","article-title":"Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: an analysis of data from the RADAR prostate radiotherapy trial","volume":"116","author":"Yahya","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0575","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13014-022-02003-8","article-title":"Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers","volume":"17","author":"Osman","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100980_b0580","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.meddos.2023.07.004","article-title":"Quality rectal hydrogel placement allows for gel-enabled dose-escalated EBRT (GEDE-EBRT) without rectal interference in prostate cancer","volume":"48","author":"Takayesu","year":"2023","journal-title":"Med Dosim"}],"container-title":["Physics and Imaging in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631626000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631626000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:42:31Z","timestamp":1783086151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405631626000801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":116,"alternative-id":["S2405631626000801"],"URL":"https:\/\/doi.org\/10.1016\/j.phro.2026.100980","relation":{},"ISSN":["2405-6316"],"issn-type":[{"value":"2405-6316","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External beam focal boost radiotherapy to intraprostatic lesions in prostate cancer: a scoping review","name":"articletitle","label":"Article Title"},{"value":"Physics and Imaging in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phro.2026.100980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100980"}}